Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients

Jazz Pharmaceuticals216 enrolled

Overview

To depict the incidence, outcomes and standards of care (SoC) of adenovirus (AdV) infections and associated practice patterns in allogeneic hematopoietic cell transplant recipients. It is expected that participating centers will be in the United Kingdom, France, Spain, Germany, and Italy.

Study Type

OBSERVATIONAL

Enrollment

216

Conditions

Adenovirus Infections, Human

Eligibility

Sex: ALLMin age: 0 MonthsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least one AdV positive test, regardless of specimen within 6 months following the first allo-HCT * Subjects first allo-HCT must have been performed between 1 January 2013 and 30 September 2015 Exclusion Criteria: * AdV negative

Outcomes

Primary Outcomes

Number of participants with non-relapse related mortality 3 and 6 months after first AdV Virema in paediatric allo-HCT recipients

To assess non-relapse related mortality 3 to 6 months after first adenovirus viremia.

Time frame: 3 and 6 months after first adenovirus viremia

Secondary Outcomes

Number of participants who were hospitalized To assess the number of hospitalizations

To assess the number of hospitalizations, length of stay, and ICU stay.

Time frame: 3 to 6 months

The rate of adenovirus infection progression

To assess the rate of progression to disseminated adenovirus disease within the first year following allo-HCT

Time frame: 3 to 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.